Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus Post Author:sritekinc9 Post published:May 20, 2020 Post Category:Uncategorized Post Comments:0 Comments CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 18, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). You Might Also Like Covid-19 will be with us for a long time and can easily ignite: WHO May 6, 2015 USCIS-ITServe Settlement Overturns 10 Years Of H-1B Visa Policies May 21, 2020 April’s U.S. hiring plunged 23.9% May 7, 2020 Leave a Reply Cancel replyCommentEnter your name or username Enter your email Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment. This site uses Akismet to reduce spam. Learn how your comment data is processed.
